Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial

Next Previous
X
Search
Trial Profile

Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atazanavir (Primary) ; Didanosine (Primary) ; Efavirenz (Primary) ; Emtricitabine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/zidovudine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms PEARLS

    • Most Recent Events

    • 01 Sep 2017 Results assessing the association between efavirenz metabolizer genotype and suicidality using pooled data from four clinical trials (A5095, A5142 ,A5175, A5202) published in the Journal of Infectious Diseases.
    • 26 Jul 2017 Results (n=253) of secondary analysis to understand the impact ART drugs on pregnancy and birth outcomes among women from this trial and HPTN 052 and ACTG A5208 trial, were presented at the 9th International AIDS Society Conference on HIV Science.
    • 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top